OAM
NXTC icon

Oxford Asset Management’s NextCure NXTC Stock Holding History

Oxford Asset Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-983
Closed -$364K – 1992
2019
Q3 		$364K Sell
983
-1,990
-67% -$647K 0.01% 1393
2019
Q2 		$534K Buy
+2,973
New +$618K 0.01% 1247

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oxford Asset Management's NXTC Position: Q4 2019 in Review

Oxford Asset Management sold out of NextCure (NXTC) in Q4 2019, closing a stake of 983 shares — an estimated $364K sold.

Oxford Asset Management first reported a position in NXTC in Q2 2019 and held it in 2 quarters. The position peaked at $534K in Q2 2019. 88 funds tracked by Wall St. Rank hold NXTC as of Q4 2019.

  • Oxford Asset Management reported no remaining NextCure position as of Q4 2019 after selling out during the quarter.
  • Oxford Asset Management sold 983 NextCure shares in Q4 2019, an estimated $364K.
  • Oxford Asset Management first reported a position in NextCure in Q2 2019 and held it in 2 quarters.
  • Oxford Asset Management's NextCure position peaked at $534K in Q2 2019.
  • 88 funds tracked by Wall St. Rank held NextCure as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.